News | April 03, 2026
ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
Subscribe To Our Newsletter & Stay Updated
